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To control tuberculosis (TB), it is necessary to detect the disease and provide effective treat-
ment to avert its progression and to interrupt any onward transmission from infectious
pulmonary cases. Traditional diagnostic methods rely on the detection of theMycobacterium
tuberculosis (MTB) bacilli in clinical samples such as sputum. Testing is usually done on
patients that have been coughing for some time, when transmission is likely to have
already occurred. The impact of the GeneXpert MTB/RIF assay has so far had a limited
impact on TB control because of its high cost and limited accessibility. A number of
follow-up nucleic acid amplification technologies are being evaluated, but they also rely
on testing for the presence of the bacteria in sputum. Diagnosing extra-pulmonary disease
and TB in children remains very difficult and tests are needed that detect all forms of the
disease. For developing countries with a high burden of TB, technology is needed that is
robust, affordable and will avoid diagnostic delay; the tests must be readily accessible to
the community without waiting for patients to self-refer to a TB testing clinic. Compromis-
es may be needed between accuracy and access where a rapid imperfect test that can be
used to test people in their community will have more benefit than a more perfect test that
is not accessible. Traditional serological tests have failed for TB because of the complexity
of the disease, but by testing for multiple markers, sensitivity and specificity can be
improved and it is possible to differentiate latent infection and active disease. Examples
of new assays that have the potential to change TB control shall be provided. The challenge
now is to develop, manufacture, and distribute detection platforms that are safe, robust
and affordable. Recent studies have revealed the market for TB diagnostics to be fragment-
ed and small. Consultation with manufacturers has revealed that access to finance, man-
agement of intellectual property, regulatory acceptance and in some countries the lack of
distribution networks are significant barriers to innovation. The lack of financial incentives
and expectation of poor returns on investment discourages commercial companies, and
there is a need for the not-for-profit and academic sectors to expand their role in product
development and delivery. Biologists and technologists must work with manufacturers and
healthcare providers to overcome the economic and political barriers to product develop-
ment, manufacture and distribution. To this end, guidelines and a ‘road map’ for taking
new in vitro diagnostic medical devices to market have been developed to raise awareness
and sensitize the TB research community for the need for innovation in product delivery.
 2015 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.http://dx.doi.org/10.1016/j.ijmyco.2014.11.004
